Keyphrases
Patients with Schizophrenia
79%
Elderly Patients
56%
Schizophrenia
52%
Schizophrenic Patients
42%
Antipsychotics
28%
Placebo-controlled Study
23%
Venlafaxine
23%
Quetiapine
23%
Late-onset Psychosis
23%
Donepezil
23%
Major Depressive Disorder
20%
Agitation
18%
Alzheimer's Disease Patient
16%
Dementia
15%
Neuroblastoma Cell Line
14%
Negative Sign
14%
Schizophrenia Depression
13%
Heat Shock Proteins
13%
Psychiatric Patients
13%
Symptom Scale
13%
Negative Symptoms
13%
Positive Symptoms
13%
Typical Antipsychotics
13%
Alzheimer's Disease
13%
Clinical Global Impression Scale
12%
Comorbid
11%
Heat Shock Protein 60 (HSP60)
11%
Treatment-resistant Depression
11%
Obstetric Complications
11%
Erotomania
11%
Clinical Characteristics
11%
Severe Mental Illness
11%
Folic Acid Deficiency
11%
Orchiectomy
11%
Paroxetine
11%
Imaging Characteristics
11%
Forequarter Amputation
11%
Serum Factors
11%
Blind Comparison
11%
Second Trimester
11%
Older Patients
11%
Patients at Risk
11%
Influenza Complications
11%
Electroconvulsive Therapy
11%
Palliation
11%
Hospitalization Rate
11%
Ziprasidone
11%
Depressive Episode
11%
Olanzapine
11%
Clozapine
11%
Neuroscience
Dementia Praecox
100%
Typical Antipsychotic
28%
Venlafaxine
23%
Major Depressive Disorder
18%
Neuroblastoma
14%
Cell Line
14%
Antipsychotic
14%
Heat Shock Protein
13%
Headache
11%
Depression
11%
Paroxetine
11%
Donepezil
11%
Quetiapine
11%
Placebo
11%
Natural Killer Cell
11%
Social Anxiety Disorder
11%
Negative Syndrome
10%
Positive Syndrome
10%
Olanzapine
9%
Clozapine
9%
Haloperidol
7%
Sulpiride
7%
Levosulpiride
7%
Western Blot
6%
Cognitive Disorders
5%
Pharmacology, Toxicology and Pharmaceutical Science
Symptom
34%
Alzheimer's Disease
27%
Quetiapine
23%
Venlafaxine
23%
Placebo-Controlled Study
23%
Donepezil
23%
Typical Antipsychotic
20%
Negative Syndrome
13%
Positive Syndrome
13%
Infection
11%
Folic Acid Deficiency
11%
Paroxetine
11%
Ziprasidone
11%
Depression
11%
Social Phobia
11%
Antipsychotic
10%
Clozapine
9%
Olanzapine
9%
Adverse Event
9%
Placebo
8%
Schizophrenia
7%
DSM-IV
7%
Sulpiride
7%
4 (para chlorophenyl) 1 [3 (para fluorobenzoyl)propyl] 4 piperidinol
7%
Side Effect
6%
Cognitive Defect
5%
Atypical Antipsychotics
5%
Tolerability
5%
